Medline ® Abstract for Reference 24
of 'Hyperkalemic periodic paralysis'
Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A).
Hanna MG, Stewart J, Schapira AH, Wood NW, Morgan-Hughes JA, Murray NM
J Neurol Neurosurg Psychiatry. 1998;65(2):248.
A 35 year old woman with clinical features of hyperkalaemic periodic paralysis confirmed on provocative exercise testing was investigated. DNA sequence analysis of the gene for the alpha-subunit of the skeletal muscle voltage gated sodium channel (SCN4A) on chromosome 17q23 identified a point mutation at nucleotide position 2188. This results in a threonine to methionine substitution at amino acid position 704. The patient was intolerant of diuretic medication but showed a striking clinical and electrophysiological improvement with salbutamol therapy. Treatment with beta-adrenergic agents should be considered in patients with hyperkalaemic periodic paralysis who are intolerant of, or resistant to, diuretic medications.
Department of Clinical Neurology, Institute of Neurology, London, UK. email@example.com